{"id":388060,"date":"2020-11-24T16:08:11","date_gmt":"2020-11-24T21:08:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388060"},"modified":"2020-11-24T16:08:11","modified_gmt":"2020-11-24T21:08:11","slug":"akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/","title":{"rendered":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference"},"content":{"rendered":"

<\/p>\n

\nAkero Therapeutics to Present at Evercore ISI 3rd<\/sup> Annual HealthCONx Virtual Conference\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–
\nAkero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore\u2019s 3rd<\/sup> Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020.\n<\/p>\n

\nA live webcast of the fireside chat and Q&A will be available through the investor relations section of the Company’s website at www.akerotx.com<\/a>. Following the live webcast, an archived replay will be available on the Company’s website for 30 days.\n<\/p>\n

About Akero Therapeutics<\/strong><\/p>\n

\nAkero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company\u2019s lead product candidate, Efruxifermin (EFX), formerly known as AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201124005953\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
Christina Tartaglia
\n
Stern Investor Relations, Inc.
\n
212.362.1200
\n
christina@sternir.com<\/a><\/p>\n

Media Contact:
\n<\/b>
Carolyn Hawley
\n
Canale Communications
\n
619.849.5382
\n
carolyn@canalecomm.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Health Finance Clinical Trials Pharmaceutical Cardiology Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore\u2019s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020. A live webcast of the fireside chat and Q&A will be available through the investor relations section of the Company’s website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company’s website for 30 days. About Akero Therapeutics Akero is a cardio-metabolic NASH company dedicated to reversing the escalating … <\/p>\n

Continue reading “Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388060","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore\u2019s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020. A live webcast of the fireside chat and Q&A will be available through the investor relations section of the Company’s website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company’s website for 30 days. About Akero Therapeutics Akero is a cardio-metabolic NASH company dedicated to reversing the escalating … Continue reading "Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:08:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference\",\"datePublished\":\"2020-11-24T21:08:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/\",\"name\":\"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-24T21:08:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk","og_description":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore\u2019s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020. A live webcast of the fireside chat and Q&A will be available through the investor relations section of the Company’s website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company’s website for 30 days. About Akero Therapeutics Akero is a cardio-metabolic NASH company dedicated to reversing the escalating … Continue reading \"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:08:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference","datePublished":"2020-11-24T21:08:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/","name":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-24T21:08:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201124005953r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388060"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}